Physician profile
Atara Schultz
NPI 1912112731
$357,172.20
in general payments reported to CMS, 2019-2025
8 companies · $69K in 2025
The $69K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $19K · 2021: $53K · 2022: $71K · 2023: $77K · 2024: $51K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $181K · Travel and Lodging: $11K · Food and Beverage: $3,549 · Consulting Fee: $1,400 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180,637.75 |
| Travel and Lodging | $11,113.05 |
| Food and Beverage | $3,548.87 |
| Consulting Fee | $1,400.00 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $191,051.41 | 2022-2025 | Mounjaro |
| Novo Nordisk INC | $165,503.97 | 2019-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $500.00 | 2020 | |
| Insulet Corporation | $35.10 | 2023-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $28.36 | 2019 | |
| Medtronic, INC. | $26.15 | 2023 | Minimed 780g |
| Valeritas, INC. | $14.92 | 2019 | |
| Medtronic Minimed, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atara Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.